PaTHway Phase 3 Trial Analysis

Key Secondary Endpoints: Patient Reported Symptom & Quality of Life Domains 60 50 40 HPES Symptom Physical domain score 30 20 10 0 HH HH Weeks p-value = 0.0038 50 40 HPES Symptom Cognitive domain score 30 20 10 26 0 Weeks КЯНН p-value = 0.0055 50 26 40 40 HPES Impact Physical Functioning domain score 30 20 20 HH HOH 10 10 0 Weeks p-value = 0.0046 TransCon PTH 50 50 26 HPES Impact Daily Life domain score 40 40 HH 30 30 HH 20 20 10 10 0 Weeks Placebo p-value = 0.0061 55 PaTHway TRIAL SF-36 Physical Functioning subscale score 50 45 45 40 40 35 26 26 Weeks All prespecified key secondary endpoints demonstrated statistically significant improvement compared to control P-values are TransCon PTH vs Control. For HPES, lower scores indicate improvement; for SF-36, higher scores indicate improvement. 20 Data on file, Ascendis Pharma 2022. TransCon PTH is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. p-value = 0.0347 26 ascendis pharma

View entire presentation